BACKGROUND: Variation in the glutathione S-transferase (GSTP1) gene and occupational polycyclic aromatic hydrocarbons (PAH) exposure are putative prostate cancer risk factors. An Ile/Val polymorphism in codon 105 of GSTP1 affects its enzymatic activity toward PAH detoxification, a possible mechanism in prostate carcinogenesis. METHODS: To determine whether the GSTP1 Ile105Val polymorphism modifies prostate cancer risk associated with occupational PAH exposure, we studied 637 prostate cancer cases and 244 controls of White and African-American race from the Henry Ford Health System in Detroit, Michigan. Occupational exposure to PAH from wood, petroleum, coal or other sources through respiratory and cutaneous routes was retrospectively assessed by expert review of job histories. The association of occupational PAH exposure and GSTP1 Ile105Val polymorphism with prostate cancer was tested in multiple logistic regression models adjusting for potential confounders. Cases were over sampled compared with controls to evaluate gene-environment interaction with the statistically efficient case-only analytic approach. RESULTS: Neither carriage of the GSTP1 Val(105) variant allele nor occupational PAH exposure was significantly associated with prostate cancer. However, case-only analyses revealed that carriage of the GSTP1 Val(105) variant allele was associated with increasing levels of occupational respiratory PAH exposures from any source and from petroleum (trend test p=0.01 for both). The GSTP1 Val(105) allele was observed most frequently in cases in the highest quartile of occupational respiratory PAH exposures from petroleum (OR=1.74; 95% CI=1.11-2.72) or from any source (OR=1.85; 95% CI=1.19-2.89). The gene-environment risk estimate in the highest PAH petroleum exposure quartile was greatest in men under age 60 (OR=4.52; 95% CI=1.96-10.41) or with a positive family history of prostate cancer (OR=3.02; 95% CI=1.15-7.92). CONCLUSIONS: Our results suggest men who carry the GSTP1 Val(105) variant and are exposed at high levels to occupational PAH have increased risk for prostate cancer. This increased risk is more pronounced in men under age 60 or with a family history of prostate cancer.
BACKGROUND: Variation in the glutathione S-transferase (GSTP1) gene and occupational polycyclic aromatic hydrocarbons (PAH) exposure are putative prostate cancer risk factors. An Ile/Val polymorphism in codon 105 of GSTP1 affects its enzymatic activity toward PAH detoxification, a possible mechanism in prostate carcinogenesis. METHODS: To determine whether the GSTP1Ile105Val polymorphism modifies prostate cancer risk associated with occupational PAH exposure, we studied 637 prostate cancer cases and 244 controls of White and African-American race from the Henry Ford Health System in Detroit, Michigan. Occupational exposure to PAH from wood, petroleum, coal or other sources through respiratory and cutaneous routes was retrospectively assessed by expert review of job histories. The association of occupational PAH exposure and GSTP1Ile105Val polymorphism with prostate cancer was tested in multiple logistic regression models adjusting for potential confounders. Cases were over sampled compared with controls to evaluate gene-environment interaction with the statistically efficient case-only analytic approach. RESULTS: Neither carriage of the GSTP1 Val(105) variant allele nor occupational PAH exposure was significantly associated with prostate cancer. However, case-only analyses revealed that carriage of the GSTP1 Val(105) variant allele was associated with increasing levels of occupational respiratory PAH exposures from any source and from petroleum (trend test p=0.01 for both). The GSTP1 Val(105) allele was observed most frequently in cases in the highest quartile of occupational respiratory PAH exposures from petroleum (OR=1.74; 95% CI=1.11-2.72) or from any source (OR=1.85; 95% CI=1.19-2.89). The gene-environment risk estimate in the highest PAH petroleum exposure quartile was greatest in men under age 60 (OR=4.52; 95% CI=1.96-10.41) or with a positive family history of prostate cancer (OR=3.02; 95% CI=1.15-7.92). CONCLUSIONS: Our results suggest men who carry the GSTP1 Val(105) variant and are exposed at high levels to occupational PAH have increased risk for prostate cancer. This increased risk is more pronounced in men under age 60 or with a family history of prostate cancer.
Authors: Lin Fritschi; Louise Nadon; Geza Benke; Ramzan Lakhani; Benoit Latreille; Marie-Elise Parent; Jack Siemiatycki Journal: Am J Ind Med Date: 2003-05 Impact factor: 2.214
Authors: X Hu; R O'Donnell; S K Srivastava; H Xia; P Zimniak; B Nanduri; R J Bleicher; S Awasthi; Y C Awasthi; X Ji; S V Singh Journal: Biochem Biophys Res Commun Date: 1997-06-18 Impact factor: 3.575
Authors: D Ryberg; V Skaug; A Hewer; D H Phillips; L W Harries; C R Wolf; D Ogreid; A Ulvik; P Vu; A Haugen Journal: Carcinogenesis Date: 1997-07 Impact factor: 4.944
Authors: K Sundberg; A S Johansson; G Stenberg; M Widersten; A Seidel; B Mannervik; B Jernström Journal: Carcinogenesis Date: 1998-03 Impact factor: 4.944
Authors: Cathryn Hufford Bock; Ann G Schwartz; Julie J Ruterbusch; Albert M Levin; Christine Neslund-Dudas; Susan J Land; Angela S Wenzlaff; David Reich; Paul McKeigue; Wei Chen; Elisabeth I Heath; Isaac J Powell; Rick A Kittles; Benjamin A Rybicki Journal: Hum Genet Date: 2009-07-01 Impact factor: 4.132
Authors: Christine Neslund-Dudas; Albert M Levin; Andrew Rundle; Jennifer Beebe-Dimmer; Cathryn H Bock; Nora L Nock; Michelle Jankowski; Indrani Datta; Richard Krajenta; Q Ping Dou; Bharati Mitra; Deliang Tang; Benjamin A Rybicki Journal: Prostate Date: 2014-02-05 Impact factor: 4.104
Authors: Dana Hashim; Paolo Boffetta; Matthew Galsky; William Oh; Roberto Lucchini; Michael Crane; Benjamin Luft; Jaqueline Moline; Iris Udasin; Denise Harrison; Emanuela Taioli Journal: Eur J Cancer Prev Date: 2018-07 Impact factor: 2.497
Authors: Emanuela Taioli; Rafael E Flores-Obando; Ilir Agalliu; Pascal Blanchet; Clareann H Bunker; Robert E Ferrell; Maria Jackson; La Creis R Kidd; Suzanne Kolb; Nicol A Lavender; Norma McFarlane-Anderson; Seian S Morrison; Luc Multigner; Elaine A Ostrande; Jong Y Park; Alan L Patrick; Timothy R Rebbeck; Marc Romana; Janet L Stanford; Flora Ukoli; Tiva T Vancleave; Charnita M Zeigler-Johnson; Batsirai Mutetwa; Camille Ragin Journal: Carcinogenesis Date: 2011-06-24 Impact factor: 4.944
Authors: Victoria D Balise; Chun-Xia Meng; Jennifer N Cornelius-Green; Christopher D Kassotis; Rana Kennedy; Susan C Nagel Journal: Fertil Steril Date: 2016-08-25 Impact factor: 7.329
Authors: Christine Neslund-Dudas; Albert M Levin; Jennifer L Beebe-Dimmer; Cathryn H Bock; Nora L Nock; Andrew Rundle; Michelle Jankowski; Richard Krajenta; Q Ping Dou; Bharati Mitra; Deliang Tang; Timothy R Rebbeck; Benjamin A Rybicki Journal: Cancer Causes Control Date: 2014-05-07 Impact factor: 2.506
Authors: Nora L Nock; Cathryn Bock; Christine Neslund-Dudas; Jennifer Beebe-Dimmer; Andrew Rundle; Deliang Tang; Michelle Jankowski; Benjamin A Rybicki Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506
Authors: Deliang Tang; Jason J Liu; Cathryn H Bock; Christine Neslund-Dudas; Andrew Rundle; Adnan T Savera; James J Yang; Nora L Nock; Benjamin A Rybicki Journal: Int J Cancer Date: 2007-09-15 Impact factor: 7.396
Authors: Jennifer L Beebe-Dimmer; Nora L Nock; Christine Neslund-Dudas; Andrew Rundle; Cathryn H Bock; Deliang Tang; Michelle Jankowski; Benjamin A Rybicki Journal: Urology Date: 2009-05-09 Impact factor: 2.649
Authors: Nicole A Lavender; Marnita L Benford; Tiva T VanCleave; Guy N Brock; Rick A Kittles; Jason H Moore; David W Hein; La Creis R Kidd Journal: BMC Cancer Date: 2009-11-16 Impact factor: 4.430